Technology Profiles
 Profile Detail
Fluorescent Cell Chip (FCC) technology for the preclinical research of novel pharmaceutical compounds (09 PL 61AK 3ESR)
A Polish SME active in biotechnology sector developed a method for preclinical research of pharmaceutical compounds. This testing technique based on fluorescent reporter cell lines allows for quick identification of chemical compounds that posses immunomodulatory activities. The developper offers research services in the domain of screening of chemical compounds for bioactivity and is looking for industrial partners amongst the producers of pharmaceutical, cosmetic and nutriceutical substances.
Country: Poland
Type: OFFER
Date: 26.08.2011
A Polish company offers application of its proprietary technology named Fluorescent Cell Chip (FCC) in the preclinical research of novel pharmaceutical compounds. FCC technology is based on genetically modified cell lines that express fluorescent protein in a way that mimics expression of targeted cytokines. FCC meets requirements of HTS (High Throughput Screening) platform and could be applied as primary screening of chemical libraries for immunomodulatory compounds. Data obtained with FCC point to potential immunostimulants or immunosuppressants. Such bioactivity when confirmed by additional in vitro assay allows focus on particular therapeutic application such as allergy, autoimmune disease or cancer.
Innovative Aspects:
FCC allows for quick identification of chemical compounds that posses immunomodulatory activities without animal testing. Such compounds could become candidates for new antiinflammatory, antiallergic and anticancer drugs. FCC was validated with a set of 60 chemical compounds of known bioactivities. Resultant data show a good correlation between FCC and available data on immunomodulatory and immunotoxic activities observed in vivo.
FCC could also become a valuable component of the battery of tests employed for compound profiling because it allows to better assess the risk of immunotoxicity associated with given substance. Using FCC in early phases of preclinical research will therefore minimize risk of demonstration of unexpected form of immunotoxicity in the later phase of drug development.
Degree of development:
Patents/Rights: Patent(s) applied for but not yet granted
Requested Cooperation: License Agreement, Absolutely novel process, Joint further development, Testing of new applications, Adaptation to specific needs
- Type of partner sought: industrial and/or research organization
- Specific area of activity of the partner: Industrial sectors such as chemistry, agro-food, pharmacy or cosmetics.
- Task to be performed by the partner sought: The partner should be ready to collaborate in implementation and conduction of sifting tests based on biosensors.
Type of Organisation:
Status: NEW
| 
